Diana Romero

4 days ago | tandfonline.com | Diana Romero

ABSTRACTThis paper aims to map the experience of digital literary studies (DLS) practitioners, based on the analysis of twelve semi-structured face-to-face interviews with members of the Antwerp Centre for Digital Humanities and Literary Criticism of the University of Antwerp (Belgium).

2 weeks ago | nature.com | Diana Romero

More than half of patients with relapsed and/or refractory B cell lymphomas who receive CD19-targeted chimeric antigen receptor (CAR) T cells do not have long-term remission. Furthermore, limited evidence is available on the effectiveness of subsequent treatment options for these patients, the majority of whom have CD19+ disease at relapse. Now, data from a phase I trial demonstrate that the autologous IL-18-armoured CAR T cell product huCART19-IL18 is safe and efficacious in this setting.

3 weeks ago | nature.com | Diana Romero

ERBB2 (commonly known as HER2) is mutated in 2–4% of non-small-cell lung cancers (NSCLCs). The HER2-targeted antibody–drug conjugate (ADC) trastuzumab deruxtecan (T-DXd) improves both progression-free survival (PFS) and overall survival in patients with advanced-stage NSCLC harbouring these alterations. However, T-DXd comes with a considerable risk of interstitial lung disease (ILD; including fatal events) and a high risk of grade ≥3 treatment-related adverse events (TRAEs).

Mar 7, 2025 | digitalcommons.library.tmc.edu | Jeffrey V. Lazarus |Diana Romero |Christopher J. Kopka |Salim Abdool Karim

KeywordsHumans, COVID-19, Delphi Technique, Government, Pandemics, Public Health, International Cooperation, Organizations, COVID-19 Vaccines, Communication, Health Education, Health Policy, Public OpinionAbstractDespite notable scientific and medical advances, broader political, socioeconomic and behavioural factors continue to undercut the response to the COVID-19 pandemic1,2.

Feb 20, 2025 | nature.com | Diana Romero

Chimeric proteins resulting from fusions involving NRG1, which encodes a growth factor from the EGF family, promote HER2–HER3 heterodimerization and subsequent oncogenic activation of cell proliferation. These fusions occur in <1% of solid tumours including non-small-cell lung cancer (NSCLC) and pancreatic adenocarcinoma (PDAC).